Daily Literature Update
Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies
Gladman DD, Mease PJ, Gossec L, Husni ME, Gottlieb AB, Ink B, Bajracharya R, Coarse J, Lyris N, Lambert J, Tillett W. J Rheumatol. 2025 Feb. PMID: 39892885.
Introduction
Bimekizumab shows promising sustained benefits on symptoms and work productivity in active psoriatic arthritis over 1 year.
Study Type: 2 Phase III RCTs + open-label extension
Population: bDMARD-naïve & TNFi-IR PsA patients
Intervention: Bimekizumab 160 mg SC every 4 weeks
Outcomes: Patient-reported symptoms, HRQOL, work productivity
Key Findings
- Mean pain reduction: -30.5 (bDMARD-naïve), -31.8 (TNFi-IR)
- Fatigue improved by 5.3–6.0 points
- Physical function improved (HAQ-DI -0.34 to -0.39)
- HRQOL (SF-36 PCS) increased ~8 points
- Work productivity (absenteeism, presenteeism) sustained improvement
Context & Related Research
- Coates et al., 2024: Sustained efficacy and safety in TNFi-IR patients (PMID:38388171), confirms long-term benefit.
- Rheumatology Advisor, 2024: Early and maintained PRO improvements at 52 weeks, good safety profile.
- Mease et al., 2024: Two-year data confirming persistent clinical efficacy and stable safety (PMID:39215949).
- Gladman et al., 2025: Source study with sustained PRO and work productivity gains supporting these findings (PMID:39892885).
Clinical Implications
- Bimekizumab offers durable symptom relief and functional improvement across patient subgroups.
- Improved work productivity supports its role in holistic PsA management.
- Safety profile remains favorable; monitor and manage fungal infections.
Strengths & Limitations
| Strengths | Limitations |
|---|---|
| Large phase III populations including diverse PsA patients | Open-label extension may bias longer term outcomes |
| Validated PRO and work productivity measures | Limited real-world generalizability and longer follow-up |
| Consistent treatment across trials of up to 1 year | Potential placebo influence on subjective outcomes |
Future Directions
Further long-term and real-world studies, direct comparisons with other biologics, and mechanistic research on PROs and productivity are important.
Conclusion
Bimekizumab provides sustained improvements in patient-reported symptoms, health-related quality of life, and work productivity for up to one year in patients with active psoriatic arthritis.
Listen to the Podcast
A short discussion of today’s highlight.
